FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1909938679> ?p ?o ?g. }

• W1909938679 endingPage "95" @default.
• W1909938679 startingPage "489" @default.
• W1909938679 abstract "Prolactinoma is the most frequent type of secreting pituitary tumours. In the treatment, pharmacotherapy with dopamine agonists is considered the first-line option. For many years bromocriptine, a D1 and D2 dopamine receptor agonist, has been the standard medicine for hyperprolactinemic patients. However, the treatment is frequently associated with intolerance or resistance. Recently cabergoline, a long acting, ergoline-derived, selective D2 agonist has become available and has been promoted as the initial treatment. Therefore the object of four studies was to assess the efficacy and tolerability of cabergoline in patients with prolactin-secreting pituitary adenomas. 17 patients, 13 women at the age of 21-55 years (average 37.1) and 4 men at the age of 29-45 years (average 36.3), with pathological hyperprolactinemia due to pituitary tumours were involved in the study. In all patients the increased pretreatment concentration of PRL was observed, ranging from 1047 to 1678 mlU/ml (mean 1369 mlU/ml). MRI scans revealed microprolactinomas in 11 (64.7%) cases and macroadenomas in 6 (35.3%) cases. None of the patients had previously undergone pituitary surgery and all of them were newly diagnosed, previously untreated. The patients were treated with cabergoline for 6 months. Cabergoline therapy was started at a dose of 0.5 mg twice a week for the first two months, then the dose was decreased to a 0.25 mg twice a week and finally maintained at 0.25 mg a week. After 6 months of the therapy, the normalization of serum PRL concentrations (from mean 1358 mlU/ml to mean 420 mlU/ml; p < 0.001) was achieved in 13 (76.5%) patients (8 with microprolactinoma and 5 with macroprolactinoma). In the remaining 4 patients PRL levels remained elevated but were decreased from mean 1403 mIU/ml to mean 812 mIU/ml. There were no differences, regarding CAB efficacy in lowering PRL levels, between patients with micro- and macroadenomas (p > 0.05). About 90% women resumed menstrual cycles in our study. All the other clinical pretreatment symptoms disappear in the course of the therapy. The tumour shrinkage, confirmed by control MRI was noted in 2 patients (33%) with macroprolactinoma. Cabergoline was tolerated satisfactorily by all our patients. The results have confirmed a high efficacy and a very good tolerability of CAB in the treatment of patients with pituitary adenomas. Together with a very convenient administration, such therapy can provide a very good patient compliance thus should be considered the first line option in patients with prolactinomas." @default.
• W1909938679 created "2016-06-24" @default.
• W1909938679 creator A5000899916 @default.
• W1909938679 creator A5009453314 @default.
• W1909938679 creator A5020986076 @default.
• W1909938679 creator A5057796380 @default.
• W1909938679 creator A5059670148 @default.
• W1909938679 date "2003-05-01" @default.
• W1909938679 modified "2023-10-18" @default.
• W1909938679 title "The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type." @default.
• W1909938679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14768178" @default.
• W1909938679 hasPublicationYear "2003" @default.
• W1909938679 type Work @default.
• W1909938679 sameAs 1909938679 @default.
• W1909938679 citedByCount "3" @default.
• W1909938679 countsByYear W19099386792012 @default.
• W1909938679 countsByYear W19099386792017 @default.
• W1909938679 crossrefType "journal-article" @default.
• W1909938679 hasAuthorship W1909938679A5000899916 @default.
• W1909938679 hasAuthorship W1909938679A5009453314 @default.
• W1909938679 hasAuthorship W1909938679A5020986076 @default.
• W1909938679 hasAuthorship W1909938679A5057796380 @default.
• W1909938679 hasAuthorship W1909938679A5059670148 @default.
• W1909938679 hasConcept C126322002 @default.
• W1909938679 hasConcept C126894567 @default.
• W1909938679 hasConcept C134018914 @default.
• W1909938679 hasConcept C170493617 @default.
• W1909938679 hasConcept C197934379 @default.
• W1909938679 hasConcept C2776856834 @default.
• W1909938679 hasConcept C2778258207 @default.
• W1909938679 hasConcept C2778375690 @default.
• W1909938679 hasConcept C2778918492 @default.
• W1909938679 hasConcept C2778938600 @default.
• W1909938679 hasConcept C2779064019 @default.
• W1909938679 hasConcept C2779832395 @default.
• W1909938679 hasConcept C2781449511 @default.
• W1909938679 hasConcept C71315377 @default.
• W1909938679 hasConcept C71924100 @default.
• W1909938679 hasConcept C90924648 @default.
• W1909938679 hasConceptScore W1909938679C126322002 @default.
• W1909938679 hasConceptScore W1909938679C126894567 @default.
• W1909938679 hasConceptScore W1909938679C134018914 @default.
• W1909938679 hasConceptScore W1909938679C170493617 @default.
• W1909938679 hasConceptScore W1909938679C197934379 @default.
• W1909938679 hasConceptScore W1909938679C2776856834 @default.
• W1909938679 hasConceptScore W1909938679C2778258207 @default.
• W1909938679 hasConceptScore W1909938679C2778375690 @default.
• W1909938679 hasConceptScore W1909938679C2778918492 @default.
• W1909938679 hasConceptScore W1909938679C2778938600 @default.
• W1909938679 hasConceptScore W1909938679C2779064019 @default.
• W1909938679 hasConceptScore W1909938679C2779832395 @default.
• W1909938679 hasConceptScore W1909938679C2781449511 @default.
• W1909938679 hasConceptScore W1909938679C71315377 @default.
• W1909938679 hasConceptScore W1909938679C71924100 @default.
• W1909938679 hasConceptScore W1909938679C90924648 @default.
• W1909938679 hasIssue "5" @default.
• W1909938679 hasLocation W19099386791 @default.
• W1909938679 hasOpenAccess W1909938679 @default.
• W1909938679 hasPrimaryLocation W19099386791 @default.
• W1909938679 hasRelatedWork W1909938679 @default.
• W1909938679 hasRelatedWork W1932848144 @default.
• W1909938679 hasRelatedWork W1973052272 @default.
• W1909938679 hasRelatedWork W1975966827 @default.
• W1909938679 hasRelatedWork W1991630894 @default.
• W1909938679 hasRelatedWork W2019937176 @default.
• W1909938679 hasRelatedWork W2065152265 @default.
• W1909938679 hasRelatedWork W2065213883 @default.
• W1909938679 hasRelatedWork W2107986044 @default.
• W1909938679 hasRelatedWork W2979055614 @default.
• W1909938679 hasVolume "109" @default.
• W1909938679 isParatext "false" @default.
• W1909938679 isRetracted "false" @default.
• W1909938679 magId "1909938679" @default.
• W1909938679 workType "article" @default.